>        G:\M\15\GRIFVA\GRIFVA_020.XML
>                                                      .....................................................................
>                                                          (Original Signature of Member)
>                   115TH CONGRESS
>                      1 ST SESSION
>                                        H. R.ll
>                       To amend the Federal Food, Drug, and Cosmetic Act with respect to
>                              determining the intended use of drugs and devices.
>                          IN THE HOUSE OF REPRESENTATIVES
>                       Mr. GRIFFITHintroduced the following bill; which was referred to the
>                               Committee on llllllllllllll
>                                          A BILL
>                     To amend the Federal Food, Drug, and Cosmetic Act with
>                   respect to determining the intended use of drugs and devices.
>                    1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled,
>                    3 SECTION 1. SHORT TITLE.
>                    4 This Act may be cited as the ‘‘Medical Product Com5 munications Act of 2017’’.
>        G:\VHLC\032217\032217.173.(655246|2)
> VerDate Nov 215:34 Mar 2Jkt 000PO 000Frm 000Fmt 66Sfmt 62C:\USERS\WPBURKE\APPDATA\ROAMING\SOFTQUAD\XMETAL\7.0\GEN\C\GRIFVA~1.X
>        G:\M\15\GRIFVA\GRIFVA_020.XML
>                                                 2
>                    1 SEC. 2. COMMUNICATIONS REGARDING INTENDED USES OF
>                    2 DRUGS AND DEVICES; SCIENTIFIC EX3 CHANGE.
>                    4 The Federal Food, Drug, and Cosmetic Act is amend5 ed by inserting after section 201 of such Act (21 U.S.C.
>                    6 321) the following:
>                    7 ‘‘SEC. 201A. INTENDED USES OF DRUGS AND DEVICES.
>                    8 ‘‘(a) NTENDED USE .—For purposes of this Act, in9 cluding sections 301(d), 502(f)(1), 505, 510, and 515 and
>                   10 for purposes of section 351 of the Public Health Service
>                   11 Act, the intended use of a drug, biological product, or de12 vice—
>                   13 ‘‘(1) shall be determined by reference to the ob14 jective intent of the manufacturer and sponsor of
>                   15 such drug, biological product, or device, or persons
>                   16 acting on the manufacturer’s or sponsor’s behalf, as
>                   17 demonstrated by statements contained in labeling,
>                   18 advertising, or analogous oral statements; and
>                   19 ‘‘(2) shall not be determined by reference to—
>                   20 ‘‘(A) actual or constructive knowledge of
>                   21 the manufacturer or sponsor that such drug, bi22 ological product, or device will be used in a
>                   23 manner that varies from the use approved for
>                   24 marketing under section 505, 510, or 515 of
>                   25 this Act or section 351 of the Public Health
>                   26 Service Act; or
>        G:\VHLC\032217\032217.173(655246|2)
> VerDate Nov 15:34 Mar 22Jkt 00PO 0000Frm 00Fmt 66Sfmt 62C:\USERS\WPBURKE\APPDATA\ROAMING\SOFTQUAD\XMETAL\7.0\GEN\C\GRIFVA~1.X
>        G:\M\15\GRIFVA\GRIFVA_020.XML
>                                                 3
>                    1 ‘‘(B) scientific exchange as described in
>                    2 subsection (b).
>                    3 ‘‘(b) SCIENTIFIC EXCHANGE .—
>                    4 ‘‘(1) IN GENERAL .—For purposes of this Act,
>                    5 including sections 301(d), 502(f)(1), 505, 510(k),
>                    6 and 515 and for purposes of section 351 of the Pub7 lic Health Service Act, the scientific exchange of in8 formation about a drug, biological product, or de9 vice, as described in paragraph (2), shall not con10 stitute labeling, advertising, or evidence of a new in11 tended use.
>                  12 ‘‘(2) REQUIREMENTS FOR SCIENTIFIC EX13 CHANGE .—A communication by a manufacturer or
>                  14 sponsor, or a person acting on behalf of a manufac15 turer or sponsor, about the manufacturer’s or spon16 sor’s drug, biological product, or device, or use of
>                  17 such drug, biological product, or device, that has not
>                  18 been approved for marketing under section 505,
>                  19 510, or 515 of this Act or section 351 of the Public
>                  20 Health Service Act, about a device or use of such de21 vice that has not been approved or cleared for mar22 keting under section 510 or 515 of this Act, or
>                  23 about information that is not included in the drug,
>                  24 biological product, or device labeling, constitutes sci25 entific exchange when—
>        G:\VHLC\032217\032217.173(655246|2)
> VerDate Nov 15:34 Mar 2Jkt 000PO 000Frm 000Fmt 66Sfmt 6C:\USERS\WPBURKE\APPDATA\ROAMING\SOFTQUAD\XMETAL\7.0\GEN\C\GRIFVA~1.X
>        G:\M\15\GRIFVA\GRIFVA_020.XML
>                                                   4
>                    1 ‘‘(A) the communication is supported by
>                    2 scientifically appropriate and statistically sound
>                    3 data, studies, or analyses;
>                    4 ‘‘(B) the communication includes a con5 spicuous and prominent statement that the
>                    6 drug, biological product, or device, or use of
>                    7 such drug, biological product, or device, that is
>                    8 the subject of the communication, has not been
>                    9 approved for marketing under section 505, 510,
>                   10 or 515 of this Act or section 351 of the Public
>                   11 Health Service Act, or that such communication
>                   12 includes information that is not contained in
>                   13 the drug, biological product, or device labeling,
>                   14 as applicable; and
>                   15 ‘‘(C) for communications relating to a
>                   16 drug, biological product, or device that has not
>                   17 been approved for marketing under section 505,
>                   18 510, or 515 of this Act or section 351 of the
>                   19 Public Health Service Act, or relating to a use
>                   20 of a drug, biological product, or device that has
>                   21 not been so approved, the manufacturer and
>                   22 sponsor make no claims that such product or
>                   23 use has been demonstrated to be safe or effec24 tive.
>        G:\VHLC\032217\032217.173.(655246|2)
> VerDate Nov 215:34 Mar 2Jkt 000PO 0000Frm 000Fmt 66Sfmt 6C:\USERS\WPBURKE\APPDATA\ROAMING\SOFTQUAD\XMETAL\7.0\GEN\C\GRIFVA~1.X
>        G:\M\15\GRIFVA\GRIFVA_020.XML
>                                                  5
>                    1 ‘‘(3) SCIENTIFIC EXCHANGE DESCRIBED .—The
>                    2 scientific exchange of information under paragraph
>                    3 (2) may include—
>                    4 ‘‘(A) dissemination of scientific findings in
>                    5 scientific or lay media;
>                    6 ‘‘(B) publication of results of scientific
>                    7 studies;
>                    8 ‘‘(C) letters to the editor in defense of pub9 lic challenges;
>                   10 ‘‘(D) communications at scientific or med11 ical conferences or meetings;
>                   12 ‘‘(E) dissemination of medical or scientific
>                   13 publications, reference texts, or clinical practice
>                   14 guidelines;
>                   15 ‘‘(F) communication, both proactive and
>                   16 reactive, of information regarding a manufac17 turer’s research and development efforts;
>                   18 ‘‘(G) communication, both proactive and
>                   19 reactive, of scientific, medical, or technical in20 formation or findings, including communication
>                   21 of such information by personnel in scientific,
>                   22 medical, or clinical development departments of
>                   23 manufacturers; and
>                   24 ‘‘(H) communication, both proactive and
>                   25 reactive, of health care economic and health
>        G:\VHLC\032217\032217.173.(655246|2)
> VerDate Nov 215:34 Mar 2Jkt 000PO 000Frm 000Fmt 66Sfmt 62C:\USERS\WPBURKE\APPDATA\ROAMING\SOFTQUAD\XMETAL\7.0\GEN\C\GRIFVA~1.X
>        G:\M\15\GRIFVA\GRIFVA_020.XML
>                                                  6
>                    1 outcomes information, including communication
>                    2 of such information delivered by or on behalf of
>                    3 the health care economic or health outcomes de4 partments of manufacturers to an individual,
>                    5 group of individuals, or entity responsible for
>                    6 contributing toward, advising, or facilitating de7 cisionmaking related to health care resource or
>                    8 utilization management, including decisions
>                    9 about the selection of drugs, biological products,
>                   10 or devices for a population of patients.
>                   11 ‘‘(4) RULE OF CONSTRUCTION .—Nothing in
>                   12 this subsection shall be construed—
>                   13 ‘‘(A) to authorize the Secretary to require
>                   14 that a manufacturer or sponsor submit an ap15 plication, certification, or other such submis16 sion, or to seek the Secretary’s review or ap17 proval, before, during, or subsequent to engag18 ing in scientific exchange; or
>                   19 ‘‘(B) to limit the ability of manufacturers
>                   20 or sponsors to engage in communications or ac21 tivities that properly constitute scientific ex22 change as that term is described in paragraph
>                   23 (2) but that are not specified in paragraph
>                   24 (3).’’.
>        G:\VHLC\032217\032217.173.(655246|2)
> VerDate Nov 215:34 Mar 2Jkt 000PO 000Frm 000Fmt 66Sfmt 62C:\USERS\WPBURKE\APPDATA\ROAMING\SOFTQUAD\XMETAL\7.0\GEN\C\GRIFVA~1.X
